Tempest Therapeutics Inc (TPST)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.03-1.90%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Broken: Primary pillar broken — Reduce losses and improve EPS: EPS -0.34 vs consensus -0.30.
Tempest Therapeutics aims to complete and integrate recent acquisitions to improve its position. Management targets resolving Nasdaq compliance issues to maintain market listing. Despite losses, recent EPS estimates improved from -2.76 to -1.34 for 2026. Executive transitions are underway to stabilize leadership.
The company faces serious challenges with a 56% stock drop and multiple board resignations. It is loss-making with negative EPS of -1.34 expected in 2026. Nasdaq delisting risk remains due to compliance failures. Executive instability and capital raises add uncertainty.
The market is pricing in significant risk from management instability and Nasdaq compliance issues, reflected in a 56% drawdown. Our view sees some potential in acquisition integration and EPS improvement but remains cautious given ongoing challenges.
Breaks if: integration not completed by FY26
Breaks if: EPS remains below -1.34 in FY26 or worsens in FY27
Breaks if: Continued high turnover or key executive vacancies beyond FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making and has shown volatile management performance, which adds to the uncertainty of its long-term prospects.
The market appears to be pricing in significant challenges, as evidenced by the recent earnings miss and the company's ongoing losses. Investors may expect continued volatility and a cautious approach from management in the near term.
Fundamentals are likely to remain under pressure due to the company's recent weak performance and high risk of missing earnings expectations. Management's focus on clinical development and integration of acquired assets is ongoing but has mixed results.
The thesis hinges on management's ability to execute on clinical trials and partnerships, as well as external factors like sector performance and economic conditions. A potential cut in guidance or continued weakness in job reports could negatively impact sentiment.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. This change is driven by the latest earnings miss. The company reported an EPS of -0.34, which was below the consensus estimate of -0.30. This performance indicates ongoing challenges in improving profitability.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Nasdaq delisting or failure to resolve compliance by Q4 2026
Over the next 1 to 3 years, TPST faces significant challenges but also opportunities if sector trends remain favorable. Not investment advice.